ReviewJournal of controlled release : official journal of the Controlled Release Society2013
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Comprehensive analysis of the tumor targeting efficiency of functionalized nanoparticles in an immunocompetent environment.Scientific reports · 2025Article
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Supramolecular interaction in the action of drug delivery systems.Chemical science · 2024Review
- Anti-lymphangiogenesis for boosting drug accumulation in tumors.Signal transduction and targeted therapy · 2024Article
- Nanotherapeutic Heterogeneity: Sources, Effects, and Solutions.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer.Current topics in medicinal chemistry · 2024Review
- Establishing a simple perfusion cell culture system for light-activated liposomes.Scientific reports · 2023Article
- Stimuli-responsive crosslinked nanomedicine for cancer treatment.Exploration (Beijing, China) · 2022Review
- [Research progress on the fluorescence resonance energy transfer-based polymer micelles as drug carriers].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022Review
- Multipotent Poly(Tertiary Amine-Oxide) Micelles for Efficient Cancer Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- An Overview of Nanotechnologies for Drug Delivery to the Brain.Pharmaceutics · 2022Review
- Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems.Advanced drug delivery reviews · 2021Review
- Pharmaceutical Aspects of Nanocarriers for Smart Anticancer Therapy.Pharmaceutics · 2021Review
- Polyamide/Poly(Amino Acid) Polymers for Drug Delivery.Journal of functional biomaterials · 2021Review
- Organ-on-a-chip technology for nanoparticle research.Nano convergence · 2021Review
- Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect.Pharmaceutics · 2021Review
- Screening of novel alkaloid inhibitors for vascular endothelial growth factor in cancer cells: an integrated computational approach.Genomics & informatics · 2021Article
- Hydroxyethyl starch based smart nanomedicine.RSC advances · 2021Review
- Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors.Frontiers in pharmacology · 2021Review
- The Advances of Neutrophil-Derived Effective Drug Delivery Systems: A Key Review of Managing Tumors and Inflammation.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.